Novartis
NVS
#60
Rank
$215.87 B
Marketcap
$107.85
Share price
2.72%
Change (1 day)
4.39%
Change (1 year)

Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.

P/E ratio for Novartis (NVS)

P/E ratio as of May 2025 (TTM): 17.8

According to Novartis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.7648. At the end of 2022 the company had a P/E ratio of 28.4.

P/E ratio history for Novartis from 2001 to 2024

PE ratio at the end of each year

Year P/E ratio Change
202228.4248.54%
20218.16-69.33%
202026.643.55%
201918.5
201722.9-0.9%
201623.1121.85%
201510.4-47.1%
201419.72.68%
201319.230.37%
201214.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
10.9-38.81%๐Ÿ‡บ๐Ÿ‡ธ USA
29.4 65.27%๐Ÿ‡บ๐Ÿ‡ธ USA
16.1-9.14%๐Ÿ‡บ๐Ÿ‡ธ USA
18.9 6.13%๐Ÿ‡ซ๐Ÿ‡ท France
29.4 65.22%๐Ÿ‡ฌ๐Ÿ‡ง UK
-19.9-211.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
16.5-7.33%๐Ÿ‡บ๐Ÿ‡ธ USA
16.6-6.39%๐Ÿ‡บ๐Ÿ‡ธ USA
29.2 64.24%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.